Skip to main content

Table 2 Kaplan-Meier survival analysis for overall (OS), disease-free (DFS) and local-recurrence free (LRF) survival relative to gene expressions (n): number of patients

From: Expression of TRF2 and its prognostic relevance in advanced stage cervical cancer patients

  OS means (months) 95% CI (months) OS (5 years)% p-value
TRF2 (n)     
High expression (13) 73.0 58.1 – 87.8 69.2 0.154
Low expression (7) 49.9 27.9 – 71.9 28.6
Bcl-xL (n)     
High expression (11) 46.5 30.4-62.7 27.3 0.002*
Low expression (9) 86.8 77.7-95.9 88.9
p53 (n)     
High expression (9) 48.6 29.3-67.9 33.3 0.02*
Low expression (11) 78.1 64.2-91.9 72.7
  DFS means (months) 95% CI (months) DFS (5 years)% p-value
TRF2 (n)     
High expression (13) 70.3 53.3 – 87.3 69.2 0.124
Low expression (7) 43.9 21.1 – 66.8 28.6
Bcl-xL (n)     
High expression (11) 41.1 23.9-58.4 27.3 0.003*
Low expression (9) 84.8 72.0-97.5 88.9
p53 (n)     
High expression (9) 45.8 25.7-66 33.3 0.04*
Low expression (11) 73.4 55.4-91.2 72.7  
  Local control means (months) 95% CI (months) LRF (5 years)% p-value
TRF2 (n)     
High expression (13) 58.7 44.4-72.9 76.9 0.750
Low expression (7) 54.5 32.2-76.9 57.1
Bcl-xL (n)     
High expression (11) 45.4 26.4-64.3 45.5 0.01*
Low expression (9) 71.6 66.0-77.0 88.9
p53 (n)     
High expression (9) 49.5 28.4-70.7 55.6 0.10
Low expression (11) 43.4 30.7-76 72.7
  1. *Correlation is significant at the 0.05 level (2-tailed).
\